Nuvaira

7 articles about Nuvaira

• Nuvaira Announces Published Two-Year Results in COPD Patients treated with Targeted Lung Denervation

  11/23/2020

  Nuvaira , a developer of novel therapeutic strategies to treat obstructive lung diseases, announced today publication of two-year follow-up data from its randomized, sham-controlled, double-blinded tri

• Nuvaira Announces FDA Breakthrough Designation for AIRFLOW-3 Pivotal Trial Device

  6/8/2020

  Nuvaira , a developer of novel therapeutic strategies to treat obstructive lung diseases, has announced that its Nuvaira® Lung Denervation System has been designated as a Breakthrough Device by the U.S. Food and Drug Administration (

• Nuvaira Announces Chief Financial Officer and Pivotal Study Milestone

  2/4/2020

  Nuvaira, a developer of novel therapeutic strategies to treat obstructive lung diseases, has announced that Tom Griffin has joined Nuvaira as Chief Financial Officer.

• Nuvaira Announces Peer-Reviewed Publications of Targeted Lung Denervation Mechanisms of Action and Clinical Outcomes

  8/19/2019

   Nuvaira, a developer of novel therapeutic strategies to treat obstructive lung diseases, announced today multiple peer-reviewed publications that provide further evidence of the safety, clinical effectiveness, and mechanisms of action of Targeted Lung Denervation (TLD) therapy in COPD.

• First patients successfully treated in the Nuvaira AIRFLOW-3 COPD pivotal trial

  6/10/2019

  A first for Temple University Hospital and U.S. Patients

• Nuvaira Announces a $79 Million Financing Round to Pursue Groundbreaking Treatment of COPD

  2/11/2019

  Market Development Veteran Lisa Rogan Joins Nuvaira's Executive Team

• Nuvaira Announces Enrollment Completion In First Sham-Controlled Clinical Trial Of Targeted Lung Denervation For COPD

  6/27/2017